StockData
Bicycle Therapeutics PLC logo

Bicycle Therapeutics PLC (BCYC) stock

BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3081% below fair value
$3.05−0.06 (-1.93%)

Close on Nov 19, 2026Market cap $213.79MP/E –Yield 0.00%

Bicycle Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Bicycle Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$177.04M. For fiscal 2025 it was -$252.03M. The highest annual figure on record is -$2.53M in fiscal 2017.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$252.03M–
FY2024Dec 31, 2024-$165.96M–
FY2023Dec 31, 2023-$63.56M–
FY2022Dec 31, 2022-$105.10M–
FY2021Dec 31, 2021-$16.82M–
FY2020Dec 31, 2020-$18.99M–
FY2019Dec 31, 2019-$30.17M–
FY2018Dec 31, 2018-$27.26M–
FY2017Dec 31, 2017-$2.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$40.61M–
Q2 FY2026Jun 30, 2026-$49.87M–
Q1 FY2026Mar 31, 2026-$66.64M–
Q4 FY2025Dec 31, 2025-$19.92M–
Q3 FY2025Sep 30, 2025-$71.85M–
Q2 FY2025Jun 30, 2025-$73.28M–
Q1 FY2025Mar 31, 2025-$86.97M–
Q4 FY2024Dec 31, 2024-$9.76M–
Q3 FY2024Sep 30, 2024-$40.27M–
Q2 FY2024Jun 30, 2024-$45.05M-233.2%
Q1 FY2024Mar 31, 2024-$70.88M–
Q4 FY2023Dec 31, 2023-$47.34M–
Q3 FY2023Sep 30, 2023-$1.53M–
Q2 FY2023Jun 30, 2023$33.82M–
Q1 FY2023Mar 31, 2023-$48.51M–
Q4 FY2022Dec 31, 2022-$31.76M–
Q3 FY2022Sep 30, 2022-$8.86M-141.1%
Q2 FY2022Jun 30, 2022-$33.33M–
Q1 FY2022Mar 31, 2022-$31.16M–
Q4 FY2021Dec 31, 2021-$11.50M–
Q3 FY2021Sep 30, 2021$21.55M–
Q2 FY2021Jun 30, 2021-$12.54M–
Q1 FY2021Mar 31, 2021-$14.33M-168.8%
Q4 FY2020Dec 31, 2020-$17.10M–
Q3 FY2020Sep 30, 2020-$10.08M–
Q2 FY2020Jun 30, 2020-$12.65M–
Q1 FY2020Mar 31, 2020$20.84M–
Q4 FY2019Dec 31, 2019-$5.31M–
Q3 FY2019Sep 30, 2019-$11.17M–
Q2 FY2019Jun 30, 2019-$8.07M–
Q1 FY2019Mar 31, 2019-$5.62M–
Q4 FY2018Dec 31, 2018-$9.26M–
Q3 FY2018Sep 30, 2018-$4.78M–

More Bicycle Therapeutics figures

See a number that looks wrong?